Bausch Health Companies Inc. (BHC)

NYSE: BHC · IEX Real-Time Price · USD
7.43
+0.05 (0.68%)
Jul 19, 2024, 12:09 PM EDT - Market open
0.68%
Market Cap 2.73B
Revenue (ttm) 8.97B
Net Income (ttm) -455.00M
Shares Out 366.80M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE 1.89
Dividend n/a
Ex-Dividend Date n/a
Volume 1,212,142
Open 7.38
Previous Close 7.38
Day's Range 7.36 - 7.51
52-Week Range 6.05 - 11.46
Beta 0.77
Analysts Buy
Price Target 11.67 (+57.07%)
Earnings Date Aug 1, 2024

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]

Sector Healthcare
CEO Thomas J. Appio
Employees 20,270
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2023, BHC's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is $11.67, which is an increase of 57.07% from the latest price.

Price Target
$11.67
(57.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bausch Health Welcomes Two New Members to the Executive Leadership Team

LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charho...

5 hours ago - Accesswire

Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarte...

8 days ago - Business Wire

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conf...

8 days ago - Accesswire

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals

LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced t...

4 weeks ago - Accesswire

Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better heal...

4 weeks ago - Accesswire

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting dat...

2 months ago - Accesswire

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors...

2 months ago - Accesswire

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigat...

2 months ago - Accesswire

Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chron...

2 months ago - Accesswire

Bausch Health Announces First Quarter 2024 Results

First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis GAAP Net Loss Attributable...

2 months ago - Accesswire

Bausch Health to Announce First-Quarter 2024 Results on May 2

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a confere...

Other symbols: NHC
3 months ago - Accesswire

Bausch wins US appeal to block Alvogen generic of diarrhea drug

A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.

3 months ago - Reuters

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for ...

3 months ago - Accesswire

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgari...

3 months ago - Accesswire

Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today...

3 months ago - Accesswire

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budeso...

3 months ago - Accesswire

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report LAVAL, QC / ACCESSWIRE / April 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (...

3 months ago - Accesswire

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium...

4 months ago - Business Wire

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 inve...

4 months ago - Accesswire

New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology busin...

4 months ago - Accesswire

Bausch Health Companies to Present at Cowen Annual Health Care Conference

LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference...

5 months ago - Accesswire

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. ...

5 months ago - Business Wire

Bausch + Lomb CEO Brent Saunders goes one-on-one with Jim Cramer

Bausch + Lomb Chairman and CEO Brent Saunders joins 'Mad Money' host Jim Cramer to talk earnings.

5 months ago - CNBC Television

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis Full-Ye...

5 months ago - Accesswire

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-qua...

5 months ago - Business Wire